Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Springer
    Der Anaesthesist 46 (1997), S. 195-200 
    ISSN: 1432-055X
    Keywords: Schlüsselwörter Kombinierter Ischiadikus/3-in-1-Block ; Dosiserhöhung ; Klinische Effektivität ; Key words Combined 3-in-1/sciatic nerve block ; Increasing dosage ; Clinical effectiveness
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Abstract The objective of the study was to investigate the clinical effectiveness of increasing the dosage of prilocaine for a combined 3-in-1/sciatic nerve block from 500 to 650 mg (open study with 29 patients compared with 30 patients from a former study) and to validate these findings in a second stage (randomised study comparing two groups of 30 patients each). Not only was clinical effectiveness improved by increasing the dose to 650 mg, but methaemoglobinaemia and toxicity were not relevant problems. With the higher dosage, development of the block was slightly faster (onset and completion); there were fewer unsatisfactory blocks; and clinically relevant plasma levels of methaemoglobin did not occur.
    Notes: Zusammenfassung Ziel der Studie: Ziel dieser Untersuchungen war es, in einer ersten Studie die klinische Effektivität einer Dosiserhöhung beim kombinierten Ischiadikus/3-in-1-Block von 500 mg auf 650 mg nachzuweisen (offene Studie mit 29 Patienten im Vergleich zu 30 Patienten aus einer früheren Studie) und die Ergebnisse in einer zweiten Studie (jetzt randomisierter 2 Gruppen-Vergleich mit je 30 Patienten) zu validieren. Ergebnisse: Es kann gezeigt werden, daß durch die Dosiserhöhung auf 650 mg nicht nur die klinische Effektivität zu steigern ist, sondern daß auch keine relevante Methämoglobinämie oder Toxizität auftritt. Die Blokkadeentwicklung war etwas schneller (Beginn und Zeit bis zur vollständigen Blockade), unvollständige Blockaden waren seltener, und es wurden in der Tat keine klinisch relevanten Methämoglobinspiegel gemessen.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1434-9949
    Keywords: Auranofin ; Gold Sodium Thiomalate ; Rheumatoid Arthritis ; Treatment ; Long-term Treatment ; Gold Salts
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary One hundred twenty-one patients with active RA were randomly assigned to receive 6 mg auranofin (AF)/day (60 patients) or 50 mg gold sodium thiomamate (GST)/week (62 patients) in a double-blind fashion. There were no intergroup differences with respect to sex, age, duration (median 2 years), stage and activity of the disease. In the case of “striking improvement” after 24 weeks a dose reduction to 50 mg GST/month or 4 mg AF/day was allowed and carried out in all GST patients and no AF patient. The serum gold levels were 5 times higher with weekly GST, they approached those of the AF group with monthly GST injections. The clinical parameters — number of swollen joints, activity index, articular index, grip strength, ESR — improved significantly in both groups, but grip strength, articular index and ESR improved more pronounced in the GST group. The X-ray progression (hands and forefeet) was significantly greater in the AF group. Fourthy eight AF patients (80%) and 39 GST patients (36%) completed the first year. Thereafter the study was continued as an open study but the patients were allowed to switch from GST to AF. After the first and second year 14/7 GST patients switched to AF. The second/third year was completed by 37/22 AF pat. (62%/37%) and by 15/8 GST pat. (24%/13%). Skin reactions were more common with GST (41.9%/26.7%), diarrhoea was more common with AF (36.7%/19.4%), proteinuria occurred in 10% in both groups, leucopenia and thrombocytopenia were rare in both groups (1.7%). The withdrawal rate due to adverse events was 10%/26% in the AF/GST group during the first year (p〈0.05) and 25%/32% over the three year period (n.s.). Conclusion Both AF and GST are effective in the long-term treatment of RA, but GST is more so in radiological progression and ESR.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Electronic Resource
    Electronic Resource
    Springer
    Clinical rheumatology 6 (1987), S. 35-42 
    ISSN: 1434-9949
    Keywords: Rheumatoid Arthritis ; Disease Modifying Anti-rheumatic Drugs ; Longterm Therapy ; Post-Marketing Surveillance Program ; Rheumatologic Documentation and Information System ; Medical Auditing
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary The results of longterm therapy with the oral gold preparation auranofin in patients with rheumatoid arthritis (RA) were evaluated based on the following data: 1) Two multicenter open uncontrolled studies (MTC06) and (162EMUA-RA), 2) the reevaluation ot these data for the MTC06 study after 4 years from the beginning of the study and 3) the results of a postmarketing surveillance program (PMSP) of patients on auranofin therapy. The specific rheumatologic documentation and information system (IKR inhaltkodierte rheumatologie) serves as the basis of the follow-up studies and longterm observations. The first year data on 207 patients (MTC06) indicating that duration of the disease less than 2 years was the only discriminating factor regarding a positive treatment outcome were confirmed by the two-year (151 patients). Patients, who responded favourably to Auranofin did usually well for the four-year or longer observation period. The data base of these two studies and the PMSP failed to outline any new severe or threatening side effects. Diarrhea and loose stools were more common at the beginning of the treatment. The overall withdrawal for untoward events was 11.2%. Patients who did or did not respond to previous DIMARD therapy either on i. m. gold, D-Penicillamine or Chloroquine, did usually well when treated with Auranofin, even if severe side effects leading to withdrawal had occurred on previous therapy. The favourable safety profile was confirmed by the PMSP data.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...